Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLGNNASDAQ:MHUANASDAQ:NXLNASDAQ:PYPD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLGNCollPlant Biotechnologies$1.41-4.1%$2.05$1.35▼$5.48$18.69M1.7533,268 shs106,180 shsMHUAMeihua International Medical Technologies$0.42+2.5%$0.37$0.25▼$1.47$13.07M0.84688,898 shs52,691 shsNXLNexalin Technology$1.05+1.0%$1.37$0.59▼$4.49$17.86M4.02881,192 shs78,199 shsPYPDPolyPid$3.68+12.2%$2.94$2.30▼$4.49$33.43M1.25128,184 shs563,264 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLGNCollPlant Biotechnologies-4.08%-14.55%-26.94%-49.64%-70.90%MHUAMeihua International Medical Technologies+6.33%+13.51%+10.24%+20.48%-48.50%NXLNexalin Technology+0.96%-11.76%-14.63%-51.39%-35.98%PYPDPolyPid+12.20%+0.27%+32.42%+31.43%-13.62%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLGNCollPlant Biotechnologies1.7751 of 5 stars3.73.00.00.00.60.00.6MHUAMeihua International Medical TechnologiesN/AN/AN/AN/AN/AN/AN/AN/ANXLNexalin Technology1.7474 of 5 stars3.53.00.00.00.61.70.0PYPDPolyPid2.8669 of 5 stars3.65.00.00.02.11.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLGNCollPlant Biotechnologies 3.33Buy$11.50715.60% UpsideMHUAMeihua International Medical Technologies 0.00N/AN/AN/ANXLNexalin Technology 3.00Buy$5.00376.19% UpsidePYPDPolyPid 3.17Buy$11.80220.65% UpsideCurrent Analyst Ratings BreakdownLatest MHUA, CLGN, PYPD, and NXL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/18/2025PYPDPolyPidRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$12.00 ➝ $9.006/17/2025PYPDPolyPidJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$16.00 ➝ $14.006/9/2025PYPDPolyPidHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$11.00 ➝ $13.006/5/2025PYPDPolyPidRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$9.006/2/2025PYPDPolyPidHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$11.005/28/2025CLGNCollPlant BiotechnologiesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$14.00 ➝ $12.004/14/2025PYPDPolyPidHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $11.003/27/2025CLGNCollPlant BiotechnologiesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.003/24/2025NXLNexalin TechnologyMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$5.00(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLGNCollPlant Biotechnologies$510K35.17N/AN/A$1.18 per share1.19MHUAMeihua International Medical Technologies$96.90M0.14$0.47 per share0.90$6.34 per share0.07NXLNexalin Technology$170K106.11N/AN/A$0.28 per share3.75PYPDPolyPidN/AN/AN/AN/A$0.75 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLGNCollPlant Biotechnologies-$16.61M-$1.22N/AN/AN/A-560.92%-87.33%-65.31%7/16/2025 (Estimated)MHUAMeihua International Medical Technologies$10.84MN/A0.00∞N/AN/AN/AN/AN/ANXLNexalin Technology-$7.61M-$0.83N/A∞N/A-6,529.77%-277.92%-245.37%8/14/2025 (Estimated)PYPDPolyPid-$29.02M-$4.30N/A∞N/AN/A-1,069.37%-151.85%8/13/2025 (Estimated)Latest MHUA, CLGN, PYPD, and NXL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/4/2025Q1 2025CLGNCollPlant Biotechnologies-$0.37-$0.13+$0.24-$0.13$9.76 million$2.06 million5/14/2025Q1 2025PYPDPolyPid-$0.80-$0.70+$0.10-$0.70N/AN/A5/13/2025Q1 2025NXLNexalin Technology-$0.10-$0.15-$0.05-$0.15$0.04 million$0.04 million3/26/2025Q4 2024CLGNCollPlant Biotechnologies-$0.42-$0.34+$0.08-$0.34$0.36 million$0.17 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLGNCollPlant BiotechnologiesN/AN/AN/AN/AN/AMHUAMeihua International Medical TechnologiesN/AN/AN/AN/AN/ANXLNexalin TechnologyN/AN/AN/AN/AN/APYPDPolyPidN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLGNCollPlant BiotechnologiesN/A4.484.23MHUAMeihua International Medical TechnologiesN/A5.265.21NXLNexalin TechnologyN/A4.564.25PYPDPolyPid4.430.710.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLGNCollPlant Biotechnologies21.69%MHUAMeihua International Medical Technologies1.17%NXLNexalin Technology0.65%PYPDPolyPid26.47%Insider OwnershipCompanyInsider OwnershipCLGNCollPlant Biotechnologies9.60%MHUAMeihua International Medical Technologies66.56%NXLNexalin Technology25.26%PYPDPolyPid24.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLGNCollPlant Biotechnologies7012.72 million11.50 millionOptionableMHUAMeihua International Medical Technologies62031.90 million10.67 millionNot OptionableNXLNexalin Technology317.18 million12.84 millionNot OptionablePYPDPolyPid8010.19 million7.67 millionNo DataMHUA, CLGN, PYPD, and NXL HeadlinesRecent News About These CompaniesBrokerages Set PolyPid Ltd. (NASDAQ:PYPD) PT at $11.25June 20, 2025 | americanbankingnews.comPolyPid (NASDAQ:PYPD) Price Target Lowered to $9.00 at Roth CapitalJune 19, 2025 | americanbankingnews.comPolyPid Secures $26.7 Million in Additional Funding to Extend Runway Ahead of D-PLEX₁₀₀ FDA ApprovalJune 18, 2025 | nasdaq.comPolyPid (NASDAQ:PYPD) Price Target Cut to $14.00 by Analysts at JMP SecuritiesJune 18, 2025 | americanbankingnews.comPolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial ResultsJune 16, 2025 | globenewswire.comFY2026 Earnings Estimate for PolyPid Issued By HC WainwrightJune 14, 2025 | americanbankingnews.comPESG Research Update: PolyPid's SHIELD II Trial Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection PreventionJune 11, 2025 | globenewswire.comPESG Research Update: PolyPid SHIELD's II Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection PreventionJune 11, 2025 | globenewswire.comPolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met ...June 11, 2025 | seekingalpha.comCraig-Hallum Reaffirms Their Buy Rating on PolyPid (PYPD)June 11, 2025 | theglobeandmail.comPolyPid reports positive phase 3 surgical infection drug trialJune 11, 2025 | en.globes.co.ilNano-Cap PolyPid's Lead Drug Candidate Cuts Surgical Infection Risk by 38% In Phase 3 TrialJune 11, 2025 | finance.yahoo.comPolyPid price target raised to $13 from $11 at H.C. WainwrightJune 11, 2025 | msn.comPolyPid shares surge on successful D-PLEX100 trial resultsJune 9, 2025 | in.investing.comBriefCast Publishes Transcript: PolyPid Ltd. SHIELD II Phase 3 Trial Topline Results Call TranscriptJune 9, 2025 | globenewswire.comPolyPid’s D-PLEX100 Achieves Positive Phase 3 Results in SHIELD II TrialJune 9, 2025 | tipranks.comPolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary EndpointsJune 9, 2025 | globenewswire.comPolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025June 8, 2025 | finance.yahoo.comPolyPid Ltd. to Host Conference Call on June 9 to Report Topline Data from SHIELD II Phase 3 Trial for D-PLEX100June 6, 2025 | quiverquant.comPolyPid to Host Conference Call and Webcast to Discuss D-PLEXâ‚₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025June 6, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMHUA, CLGN, PYPD, and NXL Company DescriptionsCollPlant Biotechnologies NASDAQ:CLGN$1.41 -0.06 (-4.08%) Closing price 06/23/2025 03:59 PM EasternExtended Trading$1.42 +0.02 (+1.06%) As of 06/23/2025 06:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; as well as develops injectable breast implants and 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures. It has collaboration agreements with Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; International Society for Biofabrication; AbbVie; and STEMCELL Technologies. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. The company was founded in 2004 and is headquartered in Rehovot, Israel.Meihua International Medical Technologies NASDAQ:MHUA$0.42 +0.01 (+2.49%) Closing price 06/23/2025 03:30 PM EasternExtended Trading$0.41 -0.01 (-2.38%) As of 06/23/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Meihua International Medical Technologies Co., Ltd. engages in the manufacture, sells, and marketing of medical consumables in the People's Republic of China. The company offers class I, II, and III disposable medical devices. Its products include non-bottled products, such as brushes and ID bracelets; and polyethylene bottled products, such as eye drop and tablet bottles, as well as electronic pumps. The company also distributes disposable medical devices sourced from other manufacturers to customers in China. In addition, it offers COVID-19 products comprising disposable medical masks. The company serves hospitals, pharmacies, medical institutions, and medical equipment companies. It also exports its products to Europe, North America, South America, Asia, Africa, and Oceania. The company was founded in 1991 and is based in Yangzhou, the People's Republic of China. Meihua International Medical Technologies Co., Ltd. operates as a subsidiary of Bright Accomplish Limited.Nexalin Technology NASDAQ:NXL$1.05 +0.01 (+0.96%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$1.18 +0.13 (+12.00%) As of 06/23/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas.PolyPid NASDAQ:PYPD$3.68 +0.40 (+12.20%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$3.68 -0.01 (-0.14%) As of 06/23/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Stock Holds Steady as AI Drives Workforce Shift Top International ETFs With Dividends and Market-Beating Returns D-Wave Goes International With South Korea Partnership BigBear.ai Poised to Benefit as Palantir Dominates AI Defense Kroger Stock Confirms Buy Signal as Uptrend Gains Strength Darden Stock Set to Sizzle After Blowout Q4 and $1B Buyback Alphabet’s Comeback: The Hidden Engines Powering Google New All-Time Highs Coming for Broadcom? Wall Street Says Yes Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
